Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $15.14.

Several brokerages have commented on CATX. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday, January 13th. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $5.00 in a research report on Monday, November 25th.

Perspective Therapeutics Trading Up 8.5 %

CATX stock opened at $3.43 on Friday. The business’s fifty day moving average price is $4.29 and its two-hundred day moving average price is $10.00. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. Equities analysts predict that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling at Perspective Therapeutics

In related news, CFO Jonathan Robert Hunt purchased 12,829 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the purchase, the chief financial officer now owns 48,800 shares in the company, valued at approximately $186,416. This trade represents a 35.66 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Heidi Henson acquired 25,975 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth $630,000. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at $117,000. Renaissance Technologies LLC boosted its stake in Perspective Therapeutics by 94.2% in the second quarter. Renaissance Technologies LLC now owns 61,660 shares of the company’s stock valued at $615,000 after acquiring an additional 29,914 shares during the last quarter. HighVista Strategies LLC bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth $1,132,000. Finally, Ally Bridge Group NY LLC purchased a new position in Perspective Therapeutics in the 2nd quarter valued at approximately $3,951,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.